% | $
Quotes you view appear here for quick access.

Biogen Inc. Message Board

  • bs572 bs572 Jun 10, 2002 6:12 PM Flag

    Street expectation is below $18 .


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • very good. I am satisfied. You are coming to the real world.
      Your price is real after comparing to the time you posted.
      Now go work harder on IDPH.
      Good luck to IDPH.

      puff .. puff

    • Price: 32.839. Number = NYOB. But I boosted my percentage holding by more than 10 and less than 20 %.

    • If memory serves, wasn't that a SLE trial for IDEC-131? I could be wrong, but I have that recollection too. If you listened to the conference call, you will have noticed that there are several drugs that we reported by whatever service it is (I forget the name) that tracks monthly meds shipments that showed very low numbers for April. Analysts don't know whether this is another tracking problem, or whether shipments really are down. And IDPH would not comment either way. So last year IDPH got hammered because those tracking numbers were overly optimistic - if the tracking numbers are looking low that could be adding to the weakness here. But we'll have to wait for DNA's earnings report in early July to know for sure. Who knows? Fog of war.

    • Oh, it is not. Jeez, if you're going to make up a bash, at least make it credible. And anyone who uses TheStreet.Com as their source for definitive biotech investing information would be better off using a ouija board. IMHO, of course. So freaking what if estimates come down a penny or two in a quarter or two - the timing of the Zevalin Medicare pass-through has nothing to do with the company's long term growth rate. The much more significant downside here is the risk that patients who would benefit from this treatment may now have to wait longer. Some don't have that kind of time. That's much more important than whether IDPH goes to 32, 34, 36, 38, or 40 tomorrow.

      More significant for the long term is the Hold on IDEC-131. Even though no one was counting on revenues from this, it is always better to have positive surprises from the pipeline than disappointments. But IDPH has shown they can manage these kinds of situations well in the past, and I expect them to do so here too. But in IDPH I'm an investor, not a trader, and a lot of traders will shoot first and never ask questions at all.

307.86+1.73(+0.57%)Aug 30 4:00 PMEDT